223 related articles for article (PubMed ID: 18772043)
1. Dopamine/serotonin releasers as medications for stimulant addictions.
Rothman RB; Blough BE; Baumann MH
Prog Brain Res; 2008; 172():385-406. PubMed ID: 18772043
[TBL] [Abstract][Full Text] [Related]
2. Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction.
Rothman RB; Blough BE; Baumann MH
Exp Clin Psychopharmacol; 2008 Dec; 16(6):458-74. PubMed ID: 19086767
[TBL] [Abstract][Full Text] [Related]
3. Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions.
Rothman RB; Blough BE; Baumann MH
AAPS J; 2007 Jan; 9(1):E1-10. PubMed ID: 17408232
[TBL] [Abstract][Full Text] [Related]
4. Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs.
Rothman RB; Baumann MH
Ann N Y Acad Sci; 2006 Aug; 1074():245-60. PubMed ID: 17105921
[TBL] [Abstract][Full Text] [Related]
5. Appetite suppressants as agonist substitution therapies for stimulant dependence.
Rothman RB; Blough BE; Baumann MH
Ann N Y Acad Sci; 2002 Jun; 965():109-26. PubMed ID: 12105089
[TBL] [Abstract][Full Text] [Related]
6. Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal.
Broderick PA; Hope O; Okonji C; Rahni DN; Zhou Y
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):157-71. PubMed ID: 14687870
[TBL] [Abstract][Full Text] [Related]
7. Effects of methcathinone and 3-Cl-methcathinone (PAL-434) in cocaine discrimination or self-administration in rhesus monkeys.
Kohut SJ; Fivel PA; Blough BE; Rothman RB; Mello NK
Int J Neuropsychopharmacol; 2013 Oct; 16(9):1985-98. PubMed ID: 23768644
[TBL] [Abstract][Full Text] [Related]
8. Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys.
Banks ML; Bauer CT; Blough BE; Rothman RB; Partilla JS; Baumann MH; Negus SS
Exp Clin Psychopharmacol; 2014 Jun; 22(3):274-284. PubMed ID: 24796848
[TBL] [Abstract][Full Text] [Related]
9. Phentermine and fenfluramine. Preclinical studies in animal models of cocaine addiction.
Rothman RB; Elmer GI; Shippenberg TS; Rea W; Baumann MH
Ann N Y Acad Sci; 1998 May; 844():59-74. PubMed ID: 9668665
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of monoamine transporter substrates.
Rothman RB; Baumann MH
Curr Top Med Chem; 2006; 6(17):1845-59. PubMed ID: 17017961
[TBL] [Abstract][Full Text] [Related]
11. Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration.
Rothman RB; Blough BE; Woolverton WL; Anderson KG; Negus SS; Mello NK; Roth BL; Baumann MH
J Pharmacol Exp Ther; 2005 Jun; 313(3):1361-9. PubMed ID: 15761112
[TBL] [Abstract][Full Text] [Related]
12. Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys.
Negus SS; Mello NK; Blough BE; Baumann MH; Rothman RB
J Pharmacol Exp Ther; 2007 Feb; 320(2):627-36. PubMed ID: 17071819
[TBL] [Abstract][Full Text] [Related]
13. The effects of the 5-HT(2C) receptor antagonist SB242084 on locomotor activity induced by selective, or mixed, indirect serotonergic and dopaminergic agonists.
Fletcher PJ; Sinyard J; Higgins GA
Psychopharmacology (Berl); 2006 Sep; 187(4):515-25. PubMed ID: 16832658
[TBL] [Abstract][Full Text] [Related]
14. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications.
Baumann MH; Ayestas MA; Dersch CM; Brockington A; Rice KC; Rothman RB
Synapse; 2000 May; 36(2):102-13. PubMed ID: 10767057
[TBL] [Abstract][Full Text] [Related]
15. Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder.
Howell LL; Cunningham KA
Pharmacol Rev; 2015; 67(1):176-97. PubMed ID: 25505168
[TBL] [Abstract][Full Text] [Related]
16. Combination of the dopaminergic agent, phentermine, and the serotonergic agent, fenfluramine, in the treatment of cocaine dependence.
Kampman KM; Volpicelli J
J Subst Abuse Treat; 1997; 14(4):401-4. PubMed ID: 9368218
[No Abstract] [Full Text] [Related]
17. Dual dopamine-5-HT releasers: potential treatment agents for cocaine addiction.
Rothman RB; Blough BE; Baumann MH
Trends Pharmacol Sci; 2006 Dec; 27(12):612-8. PubMed ID: 17056126
[TBL] [Abstract][Full Text] [Related]
18. Cocaine-like discriminative stimulus effects of "norepinephrine-preferring" monoamine releasers: time course and interaction studies in rhesus monkeys.
Kohut SJ; Jacobs DS; Rothman RB; Partilla JS; Bergman J; Blough BE
Psychopharmacology (Berl); 2017 Dec; 234(23-24):3455-3465. PubMed ID: 28889212
[TBL] [Abstract][Full Text] [Related]
19. [3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux.
Johnson RA; Eshleman AJ; Meyers T; Neve KA; Janowsky A
Synapse; 1998 Sep; 30(1):97-106. PubMed ID: 9704886
[TBL] [Abstract][Full Text] [Related]
20. Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine.
Negus SS; Baumann MH; Rothman RB; Mello NK; Blough BE
J Pharmacol Exp Ther; 2009 Apr; 329(1):272-81. PubMed ID: 19151247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
